Semax
Heptapeptide ACTH(4-10) analog with a C-terminal Pro-Gly-Pro extension. Studied in BDNF/TrkB and neurotrophic signalling models.
For laboratory research use only. Material is supplied as a research reference standard and is not approved by Health Canada. Protocols below are compiled from published literature and supplier documentation; they are reference information, not medical advice. Anyone with a health condition or on medication should speak to a physician first.
Before you begin
- • Lot-matched certificate and laboratory notebook
- • Calibrated pipettes, low-binding tubes and suitable PPE
- • Validated solvent, assay reagents and model-specific SOP
- • Appropriate positive, negative and vehicle controls
Required controls
- Vehicle-only negative control
- Untreated baseline
- Validated pathway control
- Parallel viability measurement
Reported protocol
- Standard
- 300 mcg to 600 mcg on waking
- Route
- Intranasal or subcutaneous
- Cycle length
- 14 to 21 days on, followed by 7 to 14 days off
Diluent
Sterile bacteriostatic water (0.9% benzyl alcohol) for multi-withdrawal stock, or sterile water for injection where a preservative-free stock is required by the assay.
Reconstitution concentrations
Solvent volume sets the stock concentration. Lower volume gives a more concentrated stock and smaller working aliquots; higher volume gives a more dilute stock that is easier to measure accurately.
| Solvent added | Stock concentration | Per 0.1 mL | Per unit (U-100) |
|---|---|---|---|
| 1 mL | 10 mg/mL | 1 mg | 100 mcg |
| 2 mL | 5 mg/mL | 500 mcg | 50 mcg |
| 3 mL | 3.33 mg/mL | 333.33 mcg | 33.33 mcg |